Keybank National Association OH lowered its holdings in Edwards Lifesciences Corp (NYSE:EW) by 6.0% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,820 shares of the medical research company’s stock after selling 1,271 shares during the period. Keybank National Association OH’s holdings in Edwards Lifesciences were worth $3,662,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Wendell David Associates Inc. lifted its holdings in Edwards Lifesciences by 1.7% in the 2nd quarter. Wendell David Associates Inc. now owns 12,100 shares of the medical research company’s stock valued at $2,235,000 after purchasing an additional 207 shares in the last quarter. Wetherby Asset Management Inc. increased its position in Edwards Lifesciences by 11.5% during the 1st quarter. Wetherby Asset Management Inc. now owns 3,273 shares of the medical research company’s stock worth $626,000 after purchasing an additional 337 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its position in Edwards Lifesciences by 7.7% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 19,553 shares of the medical research company’s stock worth $3,741,000 after purchasing an additional 1,403 shares in the last quarter. Ballentine Partners LLC acquired a new stake in Edwards Lifesciences during the 1st quarter worth approximately $243,000. Finally, Thoroughbred Financial Services LLC acquired a new stake in Edwards Lifesciences during the 1st quarter worth approximately $249,000. Hedge funds and other institutional investors own 82.43% of the company’s stock.

In other news, VP Catherine M. Szyman sold 372 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $214.53, for a total transaction of $79,805.16. Following the completion of the sale, the vice president now owns 18,010 shares of the company’s stock, valued at $3,863,685.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $169.60, for a total transaction of $508,800.00. Following the sale, the vice president now directly owns 20,674 shares of the company’s stock, valued at approximately $3,506,310.40. The disclosure for this sale can be found here. Insiders sold 137,951 shares of company stock valued at $27,076,240 in the last ninety days. 1.63% of the stock is owned by corporate insiders.

NYSE:EW traded up $4.80 during trading hours on Friday, hitting $220.01. The stock had a trading volume of 24,020 shares, compared to its average volume of 1,192,840. The company has a current ratio of 3.38, a quick ratio of 2.48 and a debt-to-equity ratio of 0.18. Edwards Lifesciences Corp has a 1-year low of $136.44 and a 1-year high of $219.71. The business has a 50 day simple moving average of $201.20 and a two-hundred day simple moving average of $184.95. The company has a market cap of $45.32 billion, a PE ratio of 46.76, a price-to-earnings-growth ratio of 2.76 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the company earned $1.24 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 15.2% on a year-over-year basis. Research analysts expect that Edwards Lifesciences Corp will post 5.34 EPS for the current fiscal year.

EW has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 target price for the company in a research report on Thursday, July 25th. Citigroup set a $159.00 target price on shares of Edwards Lifesciences and gave the stock a “sell” rating in a research report on Friday, July 26th. Deutsche Bank increased their target price on shares of Edwards Lifesciences from $164.00 to $184.00 and gave the stock a “hold” rating in a research report on Wednesday, April 24th. Wells Fargo & Co increased their target price on shares of Edwards Lifesciences from $207.00 to $220.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, Barclays increased their target price on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the stock an “underweight” rating in a research report on Wednesday, July 24th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $204.74.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: Do investors pay a separate front-end load every time they buy additional shares?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.